Aim: The purpose of this registry was to establish long-term safety and efficacy through implantation of Supralimus-Core sirolimus-eluting stents (SES) in real-world patients with coronary artery disease (CAD). Methods: The present registry was a retrospective, singe-arm, single-centre, investigator-initiated registry. A total of 372 consecutive patients were implanted with Supralimus-Core SES between January 2015 and November 2016. The primary endpoints were major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) and target vessel revascularization (TVR) at 24 months. The secondary endpoints were all-cause death and all separate components of the primary endpoint. Additional endpoints included events of stent thrombosis classified as definite, probable, and possible stent thrombosis. Follow-ups were conducted at 30-days, 6-months, 12-months and 24-months after the index procedure. Results: The mean age of the registry population was 56.3 ± 11.1 years. Males constituted 276 (74.2%) patients. Hypertensives, diabetics, alcoholics, tobacco chewers and smokers comprised 198 (53.2%), 160 (43.0%), 93 (25.0%), 91 (24.5%) and 88 (23.7%) of the registry population, respectively.
Introduction
Percutaneous coronary intervention (PCI) has emerged as the standard treatment for coronary artery disease (CAD) [1] . Naturally, stent design has rapidly evolved over the past decades. Bare-metal stents (BMS) were the first stents licensed for use in cardiac arteries [2] . These BMS caused neointimal hyperplasia consequential of proliferation and migration of smooth muscle cells and extracellular matrix production [3] . The resultant restenosis rates led to the downfall of BMS and inception of the drug-eluting stent (DES) era. The first generation DES incorporated release of an antiproliferative drug from a permanent polymer coated on a BMS platform. The drug sirolimus displayed efficacy in preventing hyperplasia due to vascular injury after stent implantation. Hence, it is being considered as an agent for prevention of restenosis [4] . Although these stents achieved reduced restenosis and revascularization rates, presence of the permanent polymer is linked to delayed healing, inflammatory reactions, hypersensitive reactions, and late and very late thrombosis [3] . To resolve this issue, second generation stents were introduced. These stents have the advantage of a biodegradable polymer. The polymer degrades after drug elution to avoid unfavourable effects due to their permanent existence [3] . Polymer degradation reduces local inflammatory reaction and irritation, leaving behind only a metal stent adhered to the artery wall [2] . Despite this benefit, concerns regarding long-term safety and efficacy are still prevalent.
Supralimus-Core sirolimus-eluting stent (SES) (Sahajanand Medical Technologies Pvt. Ltd., Surat, India) utilizes a 60 μm ultra-thin, L605 cobalt-chromium stent platform coated with a biodegradable polymer for delivery of sirolimus drug.
This ultra-thin platform provides flexibility for easy deliverability [3] . The serpentine strut design permits uniform stress distribution at expansion whereas alternate links permit vessel trackability [2] . The present registry aimed to establish long-term safety and efficacy through implantation with Supralimus-Core SES in a "real-world" population.
Materials and Methods

Study design and patient population
This was a retrospective, singe-arm, single-centre, investigator-initiated registry conducted at a tertiary-care centre in India. Patients, diagnosed with CAD and underwent PCI with at least one Supralimus-Core SES between January K. J. K. Jain et al. Interventional procedure and adjunctive medications All procedures and medication regimes followed standard hospital procedures.
Other devices were also permitted however, stent implantation with a Supralimus-Core SES was mandatory. Pre-procedure patients were administered a dose of 300 mg clopidogrel orally 24 hours before the procedure. An intra-arterial bolus of 100 IU/kg unfractionated heparin was administered to patients to achieve an ac- 
Results
Baseline demographic characteristics
This registry comprised of 372 patients. The mean age of the registry population was 56. 
Discussion
The purpose of the current registry was to evaluate long-term safety and efficacy of the Supralimus-Core SES in real-world patients. The low MACE rates observed at 12 (3.0%) and 24 months (3.8%) demonstrate favorable results. The ISAR-STEREO trial [6] compared strut thickness of coronary stents with stainless steel platforms. Angiographic and clinical restenosis reported were 15.0% vs. 25.8% and 8.6% vs. 13.8% in the thin and thick-strut stents, respectively. Similarly, the ISAR-STEREO 2 trial [7] reported angiographic restenosis and TVR due to restenosis 17.9% vs. 31.4% and 12.3% vs. 21.9% in the thin and thick-strut stents, respectively. These trials demonstrate that thin-strut stents elicit lower restenosis rates than thick-strut stents. In line with these findings, the 60 μm thin Supralimus-Core demonstrated 3.3% in-stent restenosis and 4.6% in-segment restenosis in the MAXIMUS study [3] . TVR was 1.1% at the 24-month follow-up in the present registry. The Supralimus-Core fairs well when compared with other SES. The MeriT-2 [11] , BIOFLOW-1 [12] and SORT OUT III [13] studies reported MACE in 15 (6.0%), 3 (10%) and 46 (3·9%) patients at 12 months, respectively. The MAXIMUS study [3] reported 4.0% MACE at 12 months whereas, the present registry reported 3.0% at 12 months. The low MACE rates observed in Supralimus-Core studies imply long-term safety and efficacy.
MACE rates are favourable with the Supralimus-Core SES even at the 24-month follow-up. The SPIRIT III [14] trial reported MACE in 49 (7.7%) and 42 (13.8%) patients in everolimus-eluting stent (EES) and paclitaxel-eluting stent (PES) groups, respectively [14] . Similarly, Erdim et al. [15] reported two-year MACE in 4 (8.3%) and 13 (16.4%) patients in SES and PES groups, respectively [15] . The SIRIUS trial [16] 
Study Limitations
The major limitation of this registry is that it is a retrospective, investigator-initiated registry. The single-arm design of the registry limits the possibility of direct comparison with other DES.
Conclusion
The current registry evidences favorable long-term results after implantation of the ultra-thin strut Supralimus-Core SES in real-world patients.
